A new study published in The New England Journal of Medicine assessed the safety of MenB-FHbp vaccine – a licensed meningococcal B vaccine targeting the factor H-binding protein, and its immunogenicity against diverse strains of group B meningococcus. This randomized trial assigned 3596 adolescents (10 to 18 years of age) to receive MenB-FHbp or hepatitis A virus vaccine and saline, and 3304 young adults (18 to 25 years of age) to receive MenB-FHbp or saline at baseline, 2 months, and 6 months. It was found that in the modified intention-to-treat population, the percentage of adolescents who had an increase in the human complement (hSBA) titer by a factor of 4 or more against each primary strain ranged from 56.0 to 85.3% after dose 2; and from 78.8 to 90.2% after dose 3. On the other hand, the percentages of young adults ranged from 54.6 to 85.6% and 78.9 to 89.7%, after doses 2 and 3, respectively. Whereas, composite responses after doses 2 and 3 in adolescents were 53.7% and 82.7%, respectively; while those in young adults were 63.3% and 84.5%, respectively. Meanwhile, responses to the 4 primary strains were predictive of responses to the 10 additional strains. Moreover, a majority of the patients who received MenB-FHbp reported mild or moderate pain at the vaccination site. Thus, it was concluded that MenB-FHbp elicited bactericidal responses against diverse meningococcal B strains after doses 2 and 3 and was associated with more reactions at the injection site than the hepatitis A virus vaccine and saline.